Related Experiment Videos
Intravenous ciprofloxacin for the treatment of severe infections
C Santini1, P Baiocchi, M Venditti
1Patologia Medica II-Università degli Studi di Roma La Sapienza, Italy.
Abstract:
Intravenous ciprofloxacin at a daily dosage of 400 mg divided in two doses was administered to 19 patients with severe infections caused by ciprofloxacin-susceptible bacteria. These infections included: 11 surgical would infections, 5 soft tissue infections, 2 respiratory tract infections, 1 urinary tract infection. The offending pathogens were: 8 coagulase-negative staphylococci, 3 Staphylococcus aureus, 3 Pseudomonas aeruginosa, 2 Proteus spp., 1 Escherichia coli, 1 Branhamella catarrhalis, 1 Klebsiella ozenae and 1 Serratia liquefaciens. Overall, 17 of 19 infections (89%) showed a satisfactory clinical response to trial therapy (15 cures and 2 improvements). Microbiological eradication was observed in 17 out of 20 isolated pathogens. Emergence of resistance to ciprofloxacin occurred in 1 coagulase-negative Staphylococcus and was associated with clinical failure. No side effects were observed. We conclude that intravenous ciprofloxacin may represent efficacious and safe therapy of severe infections; however close microbiological monitoring seems to be necessary to evaluate the emergence of resistance during quinolone therapy.
Insights
Intravenous ciprofloxacin effectively treated severe bacterial infections in 89% of patients. Close monitoring is advised due to one case of ciprofloxacin resistance emerging during treatment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Severe bacterial infections pose significant clinical challenges.
- Ciprofloxacin is a fluoroquinolone antibiotic with broad-spectrum activity.
- Evaluating the efficacy and safety of intravenous ciprofloxacin in severe infections is crucial.
Purpose of the Study:
- To assess the clinical efficacy and safety of intravenous ciprofloxacin in patients with severe bacterial infections.
- To identify the spectrum of pathogens involved in these severe infections.
- To monitor for the emergence of antibiotic resistance during ciprofloxacin therapy.
Main Methods:
- A prospective study involving 19 patients with severe infections.
- Administration of intravenous ciprofloxacin at 400 mg daily, divided into two doses.
- Clinical and microbiological assessments were performed during treatment.
Main Results:
- A satisfactory clinical response was observed in 17 out of 19 infections (89%), with 15 cures and 2 improvements.
- Microbiological eradication was achieved in 17 out of 20 isolated pathogens.
- One case of coagulase-negative Staphylococcus developed ciprofloxacin resistance, correlating with clinical failure. No adverse events were reported.
Conclusions:
- Intravenous ciprofloxacin demonstrates efficacy and safety in treating severe bacterial infections.
- Continuous microbiological monitoring is essential to detect the emergence of resistance during quinolone therapy.
- Ciprofloxacin is a viable therapeutic option for severe infections, pending resistance surveillance.